第五届董事会第十四次会议决议公告 证券代码：688366 证券简称：昊海生科 公告编号：2023-037 上海昊海生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海昊海生物科技股份有限公司（以下简称"公司"）第五届董事会第十四 次会议（以下简称"本次会议"）于2023年8月24日13:30时以现场结合通讯方式 召开，本次会议通知已于2023年8月21日以书面方式送达公司全体董事。本次会 议由董事长侯永泰先生主持，会议应参加董事11人，实际参加董事11人。本次会 议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等 法律、法规和《上海昊海生物科技股份有限公司章程》（以下简称"《公司章程》"） 的有关规定。 1.1 拟回购股份的种类 本次回购股份的种类为公司发行的人民币普通股（A股）股票。 表决情况：11票同意，0票反对，0票弃权 1.2 拟回购股份的方式 通过上海证券交易所交易系统以集中竞价交易方式回购。 二、董事会会议审议情况 经与会董事审议，做出以下决议： ...

Financial Performance - The company's total assets reached RMB 7,254.17 million, and net assets attributable to shareholders increased by RMB 1,949.07 million compared to the end of 2022[6]. - The company reported a 35.66% increase in overall revenue, attributed to the normalization of operations after previous disruptions[15]. - The company's operating revenue for the reporting period reached approximately RMB 1.31 billion, representing a year-on-year increase of 35.66%[49]. - The company reported a revenue of CNY 1.5 billion for the first half of 2023, representing a year-over-year increase of 25%[160]. - The net profit attributable to shareholders of the listed company increased by 188.94% year-on-year, amounting to approximately CNY 205.23 million[169]. - The basic earnings per share (EPS) rose to CNY 1.20, reflecting a 192.68% increase compared to the previous year[164]. - The gross margin for the first half of 2023 improved to 45%, up from 40% in the previous year[160]. - The net cash flow from operating activities increased by 147.44% year-on-year, primarily driven by significant growth in operating revenue[38]. - The company's R&D investment accounted for 7.72% of operating revenue, slightly down by 0.21 percentage points from the previous year[164]. Revenue Breakdown - Revenue from the myopia prevention and refractive correction product line was RMB 206.06 million, a year-on-year increase of 16.36%[7]. - Revenue from optical materials business was RMB 110.38 million, up 42.21% year-on-year, benefiting from the recovery of global operations[7]. - Revenue from cataract products reached RMB 259.62 million, a significant increase of 55.20% year-on-year, driven by the rapid recovery of cataract surgeries[18]. - Revenue from medical beauty and wound care products was RMB 484.87 million, an increase of 47.49% year-on-year[28]. - The revenue from the orthopedic product line was RMB 231.83 million, a year-on-year increase of 29.74%[42]. - The revenue from anti-adhesion and hemostatic products was RMB 90.74 million, reflecting a year-on-year growth of 7.87%[43]. - The company's hyaluronic acid products achieved sales revenue of RMB 255.96 million, an increase of RMB 136.55 million compared to the same period last year, representing a growth rate of 114.35%[56]. - The third-generation hyaluronic acid product "Haimi" generated sales revenue exceeding RMB 115 million, with a year-on-year growth of 377.37%[58]. - The medical chitosan product for intra-articular injection saw revenue growth of 60.77%, with sales reaching RMB 80.82 million compared to RMB 50.27 million in the previous year[60]. Market Position and Share - The company’s market share in the anti-adhesion materials segment was 29.90%, making it the largest supplier in China[43]. - The company holds a 46.54% market share in the domestic orthopedic joint injection product market, maintaining its position as the leading manufacturer for nine consecutive years[61]. - The market for external epidermal growth factor products in China was approximately CNY 823 million in 2022, projected to grow to CNY 1.813 billion by 2027, with a compound annual growth rate of about 17.11%[196]. - The company is the largest domestic producer of surgical adhesion prevention agents and a major producer of medical collagen sponge, enhancing surgical safety and recovery[185]. - The company is the largest domestic producer of orthopedic joint cavity viscoelastic supplements, addressing common degenerative joint diseases in the elderly[190]. Research and Development - The company plans to focus on the clinical trials of several innovative products, including hydrophobic aspheric toric intraocular lenses and the second-generation PRL products in the second half of 2023[32]. - Research and development expenses increased by 32.17% to RMB 101.39 million, indicating a focus on innovation[49]. - The company is investing CNY 500 million in R&D for new biopharmaceutical technologies over the next two years[160]. - The group has increased R&D investment during the reporting period to develop new technologies and products, as well as to transform core technological achievements[199]. - The company is advancing clinical trials for a new biological gel product aimed at treating retinal detachment[173]. Environmental Commitment - The environmental pollution discharge from the company and its subsidiary, Likangrui, did not exceed the standard limits during the reporting period[76]. - The company has established a water reuse system to enhance water resource utilization efficiency[95]. - The company has obtained ISO 14001 environmental management system certification, demonstrating its commitment to sustainable development[108]. - The company has implemented continuous online monitoring of major pollutants in wastewater and waste gas, ensuring compliance with environmental regulations[107]. - The company has set carbon emission reduction targets and is actively seeking ways to optimize resource usage through facility upgrades and process improvements[95]. Corporate Governance and Compliance - The company held its annual general meeting on June 12, 2023, where several key resolutions were passed, including the approval of the 2022 financial statements[80]. - The company’s board of directors was authorized to repurchase H shares during the first A-share and H-share shareholder meetings held on June 12, 2023[80]. - The semi-annual report has not been audited, ensuring transparency in financial reporting[140]. - The management has highlighted the importance of risk factors in the report, advising investors to be cautious[136]. - There are no significant risks or violations related to non-operational fund occupation by controlling shareholders or related parties[139].

Financial Performance - The company recorded a revenue of approximately RMB 1,305.71 million for the six months ended June 30, 2023, representing an increase of approximately RMB 349.44 million or 36.54% compared to the same period in 2022[1]. - Profit attributable to equity holders of the company was approximately RMB 205.24 million, a significant increase of approximately RMB 134.21 million or 188.94% compared to RMB 71.03 million in the same period last year[1]. - Basic earnings per share for the period were RMB 1.20, compared to RMB 0.41 in the same period of 2022[3]. - Gross profit for the period was RMB 926.42 million, compared to RMB 666.78 million in the same period of 2022, reflecting a strong growth in profitability[2]. - The overall gross profit margin increased to 70.95% in the reporting period, up from 69.73% in the previous year, driven by the rising revenue from hyaluronic acid products[37]. Research and Development - Research and development expenses amounted to approximately RMB 101.39 million, an increase of approximately RMB 24.68 million or 32.17% year-on-year, accounting for 7.77% of total revenue[1]. - The company is engaged in research and development of biopharmaceuticals and related services, indicating ongoing innovation efforts[7]. - R&D expenses for the period were RMB 101,391 thousand, representing a 32.2% increase compared to RMB 76,711 thousand in the same period last year[19]. - The company is focusing on expanding its ophthalmic and medical aesthetic product lines, with several key R&D projects progressing smoothly, including the registration of innovative products[38]. Assets and Liabilities - The total value of non-current assets as of June 30, 2023, was RMB 3,375.60 million, slightly up from RMB 3,360.28 million at the end of 2022[4]. - Current assets totaled RMB 3,878.57 million, an increase from RMB 3,532.12 million at the end of 2022[4]. - The company reported a net asset value of RMB 6,090.57 million as of June 30, 2023, compared to RMB 5,902.38 million at the end of 2022[5]. - Total current liabilities were approximately RMB 657.79 million, an increase of about RMB 146.51 million or 28.66% from the end of 2022, primarily due to increased dividend payables[66]. - The company's total liabilities were approximately RMB 1,163.60 million, with a debt-to-asset ratio of 16.04%, up from 14.36% at the end of 2022[71]. Market and Revenue Breakdown - Revenue from mainland China was RMB 1,059,733,000, up 34.5% from RMB 787,631,000 year-on-year[13]. - Revenue from ophthalmic products was RMB 479,149 thousand, up 35.4% from RMB 354,161 thousand year-on-year[15]. - Revenue from medical beauty and wound care products increased to RMB 483,499 thousand, a 47.8% rise from RMB 327,057 thousand in the previous year[15]. - The company continues to expand its market presence, with revenue contributions from Europe, the United States, and other regions increasing significantly[13]. Shareholder Actions - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2023[1]. - The company repurchased 575,900 H shares during the reporting period, which were subsequently canceled on June 16, 2023[7]. - The company issued 592,874 A shares under the 2021 A-share restricted stock incentive plan during the reporting period[7]. Future Outlook and Strategy - The company plans to focus on four rapidly developing treatment areas: ophthalmology, medical aesthetics, wound care, and orthopedics, emphasizing research and innovation[57]. - In the second half of 2023, the company aims to enhance integration of acquired businesses to maximize operational efficiency and core competitiveness[58]. - The company will continue to advance the clinical trials of key innovative products, including various types of intraocular lenses and myopia control products[58]. - The company is set to strengthen its brand presence in the medical aesthetics sector, particularly for its high-end hyaluronic acid products[59].

一、监事会会议召开情况 上海昊海生物科技股份有限公司（以下简称"公司"）第五届监事会第九次 会议（以下简称"本次会议"）于2023年8月17日15:30时以现场结合通讯方式召 开，本次会议通知已于2023年8月3日以书面方式送达公司全体监事。本次会议由 监事会主席刘远中先生主持，会议应参加监事5人，实际参加监事5人。本次会议 的召集、召开符合《中华人民共和国公司法》等法律、法规和《上海昊海生物科 技股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 证券代码：688366 证券简称：昊海生科 公告编号：2023-035 上海昊海生物科技股份有限公司 第五届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、监事会会议审议情况 经与会监事审议，做出以下决议： 1.审议通过《关于公司截至2023年6月30日止半年度财务报表的议案》 表决情况：5票同意，0票反对，0票弃权 财 务 报 表 具 体 情 况 请 见 公 司 于 同 日 在 上 海 证 券 交 易 所 网 站 (http://www. ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-034 上海昊海生物科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 （一）实际募集资金金额、资金到账时间 上海昊海生物科技股份有限公司（以下简称"公司"或"本公司"）经中国证 券监督管理委员会证监许可[2019]1793号文同意，由主承销商瑞银证券有限责任公 司采用向战略投资者定向配售、网下向符合条件的投资者询价配售、网上向持有上 海市场非限售Ａ股股份和非限售存托凭证市值的社会公众投资者定价发行相结合 的方式进行，向社会公开发行了人民币普通股（A股）股票17,800,000股，发行价为 每股人民币89.23元，共计募集资金总额为人民币1,588,294,000.00元，扣除券商承 销佣金及保荐费人民币46,450,107.55元和增值税2,787,006.45元后，主承销商瑞银证 券有限责任公司于2019年10月25日汇入公司募集资金监管账户中国光大银行股份 有限 ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-036 上海昊海生物科技股份有限公司 关于收到公司董事长提议回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）于2023年8月17日收 到公司董事长侯永泰先生《关于提议上海昊海生物科技股份有限公司回购公司股 份的函》。提议内容主要如下： 一、提议人提议回购股份的原因和目的 侯永泰先生基于对公司未来持续发展的信心和对公司价值的认可，为了维护 广大投资者利益，增强投资者对公司的投资信心，同时促进公司稳定健康发展， 有效地将股东利益、公司利益和员工利益紧密结合在一起，提议公司通过集中竞 价交易方式进行股份回购。回购的股份将在未来合适时机全部用于员工持股计划 及/或股权激励计划。 二、提议人的提议内容 1、回购股份的种类：公司发行的人民币普通股（A股）股票。 2023年5月5日，公司完成2021年A股限制性股票激励计划第一个归属期第一 批次的归属登记，侯永泰先生归属股份数量为2.4260万股。除上 ...

上海昊海生物科技股份有限公司独立董事 关于第五届董事会第十三次会议相关事项的独立意见 我们作为上海昊海生物科技股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》等法律法规及《上海昊海生物科技股份有限公司 章程》的相关规定，基于独立、客观判断的原则，在认真审阅公司相关材料并听 取有关说明后，对公司第五届董事会第十三次会议审议的《关于公司 2023 年半 年度募集资金存放与实际使用情况的专项报告的议案》，发表如下独立意见： 上海昊海生物科技股份有限公司 2023 年 8 月 17 日 经审查，报告期内，公司募集资金的实际存放、使用情况与公司信息披露一 致，符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》及公 司《募集资金管理制度》的相关规定，公司不存在违规使用和存放募集资金的行 为，亦不存在改变或变相改变募集资金投资项目及损害股东利益的情况。我们同 意《关于公司 2023 年半年度募集资金存放与实际使用情况的专项报告的议案》。 独立董事：郭永清、苏治、赵磊、姜志宏、杨玉社 ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-020 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 上海昊海生物科技股份有限公司（以下简称"公司"）已分别于 2023 年 3 月 25 日、2023 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露了《上 海昊海生物科技股份有限公司 2022 年年度报告》及《上海昊海生物科技股份有 限公司 2023 年第一季度报告》。为加强与投资者的深入交流，使投资者更加全面、 深入地了解公司情况，公司拟以视频录播和网络互动的方式召开 2022 年度暨 2023 年第一季度业绩说明会（以下简称"本次业绩说明会"），欢迎广大投资者积 极参与。公司现就本次业绩说明会提前向广大投资者征集相关问题，广泛听取投 资者的意见和建议。 会议召开时间：2023 年 5 月 12 日（星期五）上午 10:00-11:30 会议召开地点：上海证券交易所"上证路演中 ...

Financial Performance - The net profit attributable to shareholders for the first quarter was ¥9,613,418.44 after accounting for taxes and minority interests[6]. - The net profit attributable to shareholders of the listed company increased due to significant growth in operating income[33]. - Net profit attributable to shareholders of the listed company was ¥81,177,581.15, up 33.21% from ¥60,941,331.70 in the same period last year[41]. - The company reported a total profit of ¥112,095,668.59 for Q1 2023, compared to ¥69,806,178.33 in Q1 2022[48]. - Basic and diluted earnings per share both stood at ¥0.47, reflecting an increase driven by the growth in net profit attributable to shareholders[18][33]. - Basic earnings per share for Q1 2023 were ¥0.47, compared to ¥0.35 in the same period last year[41]. Revenue and Sales - Total operating revenue for Q1 2023 reached ¥611,252,893.65, representing a 29.06% increase compared to ¥473,617,820.88 in Q1 2022[48]. - The company experienced a significant increase in sales revenue from hyaluronic acid products due to the rapid recovery of the domestic medical beauty industry[33]. Assets and Liabilities - The total assets of the company as of March 31, 2023, amounted to ¥6,984,036,145.39, an increase from ¥6,892,398,253.88 as of December 31, 2022[12]. - The company's total assets increased by 1.33% to ¥6,984,036,145.39 compared to the end of the previous year[18]. - The total current assets increased to ¥3,660,348,521.72 from ¥3,532,115,166.92 year-over-year[12]. - The total liabilities increased to ¥1,087,042,005.92, up from ¥990,013,737.98, indicating a rise in financial obligations[18]. - The company's equity attributable to shareholders was ¥5,514,492,058.38, showing a slight decrease from the previous year's figure[18]. Cash Flow - Operating cash inflow from sales of goods and services reached ¥633,139,253.73, up from ¥511,144,187.98 in the same period last year[29]. - Net cash flow from operating activities was ¥79,930,962.49, a significant increase of 1,687.78% compared to ¥4,470,962.15 in Q1 2022[43]. - Cash flow from operating activities saw a substantial increase, attributed to the rise in operating income and previous inventory buildup[33]. - The company recorded a net cash flow from investing activities of ¥156,184,009.96, contrasting with a negative cash flow of -¥174,414,144.19 in Q1 2022[43]. Research and Development - Research and development expenses totaled ¥53,624,174.05, accounting for 8.77% of operating income, a decrease of 0.84 percentage points[18]. - Research and development expenses increased to ¥53,624,174.05 from ¥45,520,090.97, reflecting a focus on innovation[48]. Inventory and Receivables - The inventory value as of March 31, 2023, was ¥526,744,476.16, up from ¥485,238,796.88 in the previous year[12]. - The company’s accounts receivable increased to ¥415,730,029.31 from ¥381,526,389.55 year-over-year[12]. Investments - The company’s long-term equity investments decreased to ¥2,858,785.76 from ¥3,028,473.17 year-over-year[12]. - The company achieved an investment income of ¥517,071.28, down from ¥2,313,643.50 in Q1 2022[48]. Shareholder Information - The company reported a total of 8,369 ordinary shareholders at the end of the reporting period[34].

Financial Performance - The company's operating revenue for Q1 2023 reached RMB 611,252,893.65, representing a year-on-year increase of 29.06%[3] - Net profit attributable to shareholders was RMB 81,177,581.15, reflecting a growth of 33.21% compared to the same period last year[3] - Basic and diluted earnings per share were both RMB 0.47, marking a 34.29% increase from the previous year[3] - Total operating revenue for Q1 2023 reached RMB 611.25 million, a 29.1% increase from RMB 473.62 million in Q1 2022[18] - Net profit for Q1 2023 was RMB 84.95 million, up 33.9% compared to RMB 63.48 million in Q1 2022[19] - The company reported a total profit of RMB 112.10 million for Q1 2023, compared to RMB 69.81 million in Q1 2022, marking a 60.2% increase[18] Cash Flow - The net cash flow from operating activities increased significantly to RMB 79,930,962.49, a rise of 1,687.78% year-on-year[3] - Cash flow from operating activities for Q1 2023 was RMB 79.93 million, significantly higher than RMB 4.47 million in Q1 2022[22] - Cash flow from investing activities showed a net inflow of RMB 156.18 million in Q1 2023, compared to a net outflow of RMB 174.41 million in Q1 2022[21] - Cash flow from financing activities resulted in a net outflow of RMB 20.94 million in Q1 2023, an improvement from a net outflow of RMB 121.58 million in Q1 2022[23] Research and Development - Research and development expenses totaled RMB 53,624,174.05, accounting for 8.77% of operating revenue, a decrease of 0.84 percentage points year-on-year[3] - Research and development expenses increased to RMB 53.62 million in Q1 2023, representing a 17.8% rise from RMB 45.52 million in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were RMB 6,984,036,145.39, up 1.33% from the end of the previous year[3] - Current assets totaled RMB 3,660,348,521.72, up from RMB 3,532,115,166.92 in the previous period, reflecting a growth of approximately 3.63%[14] - Cash and cash equivalents were RMB 2,602,235,451.20, compared to RMB 2,544,591,061.46 at the end of 2022, indicating an increase of about 2.56%[14] - Total liabilities reached RMB 1,087,042,005.92, up from RMB 990,013,737.98, marking an increase of around 9.83%[16] - Long-term borrowings rose significantly to RMB 137,254,152.36 from RMB 43,979,665.36, indicating a substantial increase[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,369[6] - The total number of shares held by the top ten shareholders accounted for 81.53% of the total shares, indicating a high concentration of ownership[10] Market and Product Development - The increase in operating revenue was driven by the recovery of the domestic medical beauty industry and the strong market acceptance of the third-generation hyaluronic acid product "Haimai" [5] - Sales revenue from artificial lenses also saw significant growth due to an increase in cataract surgeries nationwide[5] - The company has been actively promoting its orthokeratology lens products, contributing to revenue growth in that segment[5] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[12]